+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeQuizzoneWhatsappShare Flash Reads
 

An investment firm raked in $730 million in a single day after making a huge bet on a biotech stock

Oct 22, 2019, 01:10 IST

A scientist works at Zai Lab's drug development facility in Shanghai, China October 18, 2017.Reuters

Advertisement
  • Investment firm Baker Bros. Advisors profited $730 million Monday after its stake in Seattle Genetics soared on positive drug news, according to Bloomberg data.
  • The biotech company's tucatinib treatment surpassed expectations in a recent breast cancer study and improved the condition for patients whose cancer had reached their brains, the company said.
  • Baker Bros. held a 29% stake in the company as of June 30, a position now worth about $5 billion after the positive drug news.
  • Watch Seattle Genetics trade live here.

Investment firm Baker Bros. Advisors netted a $730 million profit Monday after its stake in Seattle Genetics shot through the roof on positive drug news, according to Bloomberg data.

Seattle Genetics traded as much as 18% higher Monday after a breast cancer study found its tucatinib treatment successfully countered the spread of cancer cells. The treatment posted better-than-expected improvements for patients whose cancer had reached their brains, the company said in a release.

Baker Bros. held a 29% stake in the biotech company as of June 30, according to Bloomberg, a position worth about $5 billion after the positive drug news. Seattle Genetics is the firm's largest holding.

Read more: WeWork's IPO woes are bleeding into the biotech market - and health startups' plans to go public now look dimmer

Advertisement

Seattle Genetics stock is up roughly 79% year-to-date. Its Monday peak of $101.95 per share was a record high for the stock.

The biotech company has 12 "buy" ratings, five "hold" ratings, and one "sell" rating, with a consensus price target of $90.13, according to Bloomberg data.

The company's consensus price target jumped nearly 5% after Monday's news prompted a series of upgrades.

Now read more markets coverage from Markets Insider and Business Insider:

BANK OF AMERICA: Companies are crushing earnings season so far - but the firms missing forecasts are being punished more than usual

Advertisement

Wall Street is sounding the alarm as a key source of stock-market buying evaporates

6 principles women entrepreneurs can use to disrupt 'boys' club' industries

Markets Insider

Featured Digital Health Articles:
- Telehealth Industry: Benefits, Services & Examples
- Value-Based Care Model: Pay-for-Performance Healthcare
- Senior Care & Assisted Living Market Trends
- Smart Medical Devices: Wearable Tech in Healthcare
- AI in Healthcare
- Remote Patient Monitoring Industry: Devices & Market Trends

You are subscribed to notifications!
Looks like you've blocked notifications!
Next Article